Company news
Ultragenyx Pharmaceutical Inc. news in 2025
Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2025, newest first.
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
December 29, 2025
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 28, 2025
Tactical Resources Announces Share Consolidation
December 3, 2025
Ultragenyx to Participate in Investor Conferences in December
November 23, 2025
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
November 3, 2025
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
November 3, 2025
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
October 29, 2025
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
October 27, 2025
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
September 29, 2025
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
September 7, 2025
Ultragenyx to Participate at Investor Conferences in September
August 28, 2025
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
August 17, 2025
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
August 5, 2025
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
July 30, 2025
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
July 29, 2025
New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public
July 16, 2025
Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)
July 14, 2025
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 10, 2025
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
July 8, 2025
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
June 26, 2025
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
June 2, 2025
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
May 13, 2025
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
May 6, 2025
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
May 5, 2025
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
April 29, 2025
Ultragenyx to Participate at Investor Conferences in March
February 23, 2025
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
February 17, 2025
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
February 12, 2025
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
February 5, 2025
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Redu...
February 4, 2025
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
January 11, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Calls in 2025
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Q3 2025 Earnings Call
Nov 4, 2025
Transcript - Ultragenyx Pharmaceutical (NASDAQ:RARE) Q2 2025 Earnings Call
Aug 5, 2025
Transcript - Ultragenyx Pharmaceutical (NASDAQ:RARE) Q1 2025 Earnings Call
May 6, 2025
Transcript - Ultragenyx Pharmaceutical (NASDAQ:RARE) Q4 2024 Earnings Call
Feb 13, 2025
Transcript
Decks in 2025
- Q2 2025 Earnings Presentation
Earnings · 42 slides · Aug 5, 2025